Original research| Volume 8, ISSUE 3, P265-270, October 2014

Download started.


Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes

Published:February 18, 2014DOI:



      We investigated to clarify factors associated with the efficacy of sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor, for glycemic control including the confounding effect of concomitant drugs in patients with type 2 diabetes.


      We included type 2 diabetes patients with HbA1c levels of ≥7% who were not under insulin treatment and were administered sitagliptin (50 mg/day for 6 months). Reduction or discontinuation of insulin sensitizers was not permitted during the study period. Outcomes included HbA1c level variations and attaining a target HbA1c level of <7%. Associated factors with each outcome were examined using multivariate analysis.


      Of the 313 patients enrolled in this study, 147 (47.0%) attained HbA1c levels of <7%. High baseline HbA1c levels were associated with HbA1c level variations but inversely associated with attaining the target HbA1c level of <7%. Concomitant use of an insulin sensitizer and a α-glucosidase inhibitor and maintenance of the baseline dose of concomitant drugs were significantly associated with each outcome.


      Our results suggest that concomitant sitagliptin administration (50 mg/day) will improve glycemic control if treatment is initiated before HbA1c levels deteriorate. Other medication should be continued at initiation of sitagliptin administration.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aschner P.
        • Kipnes M.S.
        • Lunceford J.K.
        • et al.
        Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
        Diabetes Care. 2006; 29: 2632-2637
        • Watanabe K.
        • Kobayashi K.
        • Takemoto M.
        • et al.
        Sitagliptin improves postprandial hyperglycemia by inhibiting glucagon secretion in Werner syndrome with diabetes.
        Diabetes Care. 2013; 36: e119
        • Muscelli E.
        • Casolaro A.
        • Gastaldelli A.
        • et al.
        Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes mellitus.
        J. Clin. Endocrinol. Metab. 2012; 97: 2818-2826
        • Sangle G.V.
        • Lauffer L.M.
        • Grieco A.
        • et al.
        Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
        Endocrinology. 2012; 153: 564-573
        • Engel S.S.
        • Round E.
        • Golm G.T.
        • et al.
        Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.
        Diabetes Ther. 2013; 4: 119-145
        • Eurich D.T.
        • Simpson S.
        • Senthilselvan A.
        • et al.
        Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
        BMJ. 2013; 346: f2267
        • Gooβen K.
        • Gräber S.
        Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
        Diabetes Obes. Metab. 2012; 14: 1061-1072
        • Park H.
        • Park C.
        • Kim Y.
        • et al.
        Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.
        Ann. Pharmacother. 2012; 46: 1453-1469
        • Nomiyama T.
        • Akehi Y.
        • Takenoshita H.
        • et al.
        Contributed factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
        Diabetes Res. Clin. Pract. 2012; 95: e87-e88
        • Maeda H.
        • Kubota A.
        • Tanaka Y.
        • et al.
        The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
        Diabetes Res. Clin. Pract. 2012; 95: e20-e22
        • Kim S.A.
        • Shim W.H.
        • Lee E.H.
        • et al.
        Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus.
        Diabetes Metab. J. 2011; 35: 159-165
        • American Diabetes Association (ADA)
        Standards of medical care in diabetes—2009.
        Diabetes Care. 2009; 32: S13-S61
        • American Association of Clinical Endocrinologist (AACE) Diabetes Mellitus Clinical Practice Guidelines Task Force
        AACE medical guidelines for clinical practice for the management of diabetes mellitus.
        Endocr. Pract. 2007; 13: 1-68
        • Sato D.
        • Sato Y.
        • Masuda S.
        • Kimura H.
        Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan.
        Int. J. Clin. Pharm. 2012; 34: 917-924
        • Kim Y.G.
        • Hahn S.
        • Oh T.J.
        • et al.
        Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.
        Diabetologia. 2013; 56: 696-708
        • Esposito K.
        • Chiodini P.
        • Bellastella G.
        • et al.
        Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients.
        Diabetes Obes. Metab. 2012; 14: 228-233
        • Moritoh Y.
        • Takeuchi K.
        • Hazama M.
        Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
        J. Pharmacol. Exp. Ther. 2009; 329: 669-676
        • Narita T.
        • Katsuura Y.
        • Sato T.
        • et al.
        Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients.
        Diabet. Med. 2009; 26: 187-188
        • Kishimoto M.
        • Noda M.
        A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
        Cardiovasc. Diabetol. 2011; 10: 115